Activating CB 1 cannabinoid receptor has been demonstrated to produce certain therapeutic effects in animal models of Alzheimer's disease (AD). In this study, we evaluated the specific contribution of CB 1 receptor to the progression of AD-like pathology in double transgenic APP/PS1 mice. A new mouse strain was generated by crossing APP/PS1 transgenic mice with CB 1 knockout mice. Genetic deletion of CB 1 drastically reduced the survival of APP/PS1 mice. In spite that CB 1 mutant mice bearing the APP/PS1 transgene developed normally, they suddenly died within the first two months of life likely due to spontaneous seizures. This increased mortality could be related to an imbalance in the excitatory/inhibitory transmission in the hippocampus as suggested by the reduced density of inhibitory parvalbumin positive neurons observed in APP/PS1 mice lacking CB 1 receptor at 7 weeks of age. We also evaluated the AD-like phenotype of APP/PS1 mice heterozygous for the CB 1 deletion at 3 and 6 months of age. The memory impairment associated to APP/PS1 transgene was accelerated in these mice. Neither the soluble levels of Aβ or the density of Aβ plaques were modified in APP/PS1 mice heterozygous for CB 1 deletion at any age. However, the reduction in CB 1 receptor expression decreased the levels of PSD-95 protein in APP/PS1 mice, suggesting a synaptic dysfunction in these animals that could account for the acceleration of the memory impairment observed. In summary, our results suggest a crucial role for CB 1 receptor in the progression of AD-related pathological events.
Introduction
The G i/o -coupled CB 1 cannabinoid receptors are widely expressed within the central nervous system, in both neurons and glial cells. They are mostly located at the terminals of neurons where they act as modulators of excitatory and inhibitory neurotransmission, regulating important brain functions including cognition [16] . Moreover, CB 1 activity mediates protection against excitotoxicity and the induction of repair mechanisms in response to neuronal damage [24, 13] . Based on the neuroprotective properties of CB 1 receptor activation, a number of studies have explored the role of this receptor in several neurodegenerative diseases, including Alzheimer's disease (AD). AD is the most common form of dementia, histologically characterized by the dysfunctional accumulation of amyloid-β peptide (Aβ) and tau hyperphosphorylation in major brain regions contributing to memory and cognition [14, 33] . Alterations in the expression or functionality of CB 1 receptors have been described both in AD patients' brains [30, 32, 23] and AD animal models [19, 3] . Interestingly, a similar reduction in CB 1 levels was observed in both human and animal models brains at advanced stages of the AD, in contrast with the increase in CB 1 expression during the asymptomatic stages [3, 23] . These findings suggest an attempt of CB 1 receptor to compensate for the initial synaptic impairment occurring at the early asymptomatic stages of AD and reinforce the hypothesis that targeting the CB 1 receptor could offer a strategy against AD. In fact, pharmacological stimulation of CB 1 receptors with natural or synthetic agonists resulted in a reduction of the neurotoxic effect of amyloid-β peptide (Aβ) in some in vitro models [27, 8, 3, 18] and in a reversion of the Aβ-induced memory impairment in different in vivo models [3, 15, 4] . The alleviation of the AD-like symptoms in these models seems not to be directly related to a significant contribution of CB 1 receptors in Aβ production, aggregation or clearance since no modifications in such parameters were reported in two different transgenic AD models after chronic treatment with specific CB 1 agonists [3, 7] . However, a role for CB 1 receptor on APP processing cannot be completely ruled out because APP23 transgenic mice deficient for CB 1 receptor exhibited reduced APP protein levels and Aβ plaque https://doi.org/10.1016/j.bcp.2018.08.007 Received 30 May 2018; Accepted 6 August 2018 deposition, likely due to changes in intracellular APP transport, although those animals presented enhanced cognitive deficits [34] .
Considering these evidence, the aim of the present study was to further explore the specific contribution of CB 1 receptor to the progression of AD in APP/PS1 transgenic mice deficient for CB 1 receptor. We have chosen this animal model of AD because it reproduces some of the most relevant features of the disease, including cognitive impairment and Aβ plaques from the age of six months onwards [6, 2] . Aβ deposition is accompanied in APP/PS1 mice by altered mitochondria and increased oxidative damage, post-translational modifications and accumulation of altered proteins at the dystrophic neurites surrounding plaques, likely due to aberrant degradation pathways [2] . However, cognitive decline in this AD model is assumed to correlate with the levels of soluble oligomeric species, which are known to play a critical role in the AD pathogenicity [37] . Thus, we have performed a timecourse evaluation of the aberrant Aβ production and memory impairment, in CB 1 receptor deficient APP/PS1 transgenic mice.
Materials and methods

Animals
Double transgenic APP (swe)/PS1 (1dE9) (APP/PS1) mice are used in the present study as a model of familial AD because they reproduce some of the most relevant features of the disease, including cognitive impairment and several pathological alterations such as Aβ plaques, dystrophic neurites around Aβ deposition, and synaptic abnormalities from the age of six months onwards [6, 2] . A new mouse strain was generated by crossing male APP/PS1 mice purchased from Jackson Laboratories (Bar Harbor, Maine, USA) with female CB 1 knockout (−/−) mice [39] obtained from the European Mutant Mouse Archive (Helmholtz Zentrum, München, Germany), both strains in a C57BL/6 background. The resulting APP/PS1/CB 1 heterozygous (+/−) males were then crossed with wild-type (WT)/CB 1 +/− females to obtain the animals for the present study. The genotype of the pups was analyzed with the polymerase chain reaction (PCR) technique using genomic DNA isolated from tail clips obtained at postnatal day 21 or at embryonic day 13.5. Animals were maintained under standard animal housing conditions in a 12-h dark-light cycle with free access to food and water. The experiments were conducted by experienced researchers blind for the genotype of the animals. All animal procedures were carried out following the guidelines of the European Communities Council Directive 2010/63/EU and with the approval of the local ethical committee of the University of Barcelona.
Behavioral evaluation of cognitive performance: Two-object recognition test
Memory performance was evaluated in WT/CB 1 +/+, WT/CB 1 +/−, WT/CB 1 −/−, APP/PS1/CB 1 +/+ and APP/PS1/CB 1 +/− male littermates aged 3 and 6 months. On day 1, mice were placed for 9 min in a V-maze where two identical objects were situated at the end of the arms; the time that mice spent exploring each object was recorded. Twenty-four hours after the training session, animals were placed again in the V-maze where one of the two familiar objects was replaced by a novel object. The time that the animals spent exploring the two objects was recorded. Object recognition index (RI) was calculated as the difference between the time spent exploring the novel (T N ) and the familiar object (T F ) divided by the total time spent exploring the two objects [RI = (T N − T F )/(T N + T F )]. Animals exhibiting memory impairments showed a lower RI.
Brain samples collection
At the end of the behavioral testing, animals ageing 3 and 6 months were killed and their brains rapidly removed from the skull and processed for study. A group of mice, including APP/PS1/CB 1 −/−, were sacrificed at 7 weeks of age for brain samples collection. One hemisphere was dissected on ice, immediately frozen, and stored at −80°C until use. The other hemisphere was fixed in 4% paraformaldehyde and processed for immunohistochemistry.
Immunohistochemistry
Fixed tissue samples were embedded in paraffin, and coronal sections, 4 μm thick, were cut with a microtome. Consecutive de-waxed sections were incubated with 98% formic acid (Aβ, 3 min) and then treated with citrate buffer (Aβ, parvalbumin, NeuN, 20 min) to enhance antigenicity. Then endogenous peroxidases were blocked by incubation in 10% methanol-1% H 2 O 2 solution (15 min). Sections were blocked with 3% normal horse serum solution and then incubated at 4°C overnight with the primary antibodies against Aβ (clone 6F/3D 1:50, Dako, Glostrup, Denmark), parvalbumin (PV, 1:1000, Sigma-Aldrich, St Louis, MO, USA) or the neuronal marker NeuN (1:100, Millipore, Burlington, MA, USA). Sections were subsequently rinsed and incubated with biotinylated secondary antibodies (Dako). Peroxidase reaction was visualized with diaminobenzidine and H 2 O 2 . Sections were lightly counterstained with hematoxylin. After staining, the sections were dehydrated and cover-slipped for observation under a Nikon Eclipse E800 microscope (Nikon Imaging Inc., Tokyo, Japan). The cortical total Aβ burden was calculated as the percentage of the area of amyloid deposition in plaques with respect to the total cortical area (0.6 mm 
Aβ soluble quantification: enzyme-linked immunosorbent assay (ELISA)
Fresh-frozen mouse brain cortex was homogenized in 4 volumes (wt:vol) of TBS extraction buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH 7.4)), 5 mM EDTA, and protease inhibitor cocktail (Roche Molecular Systems, Pleasanton, CA, USA). Homogenate was spun 100,000 g×1 h, and the supernatant was saved as the soluble fraction for Aβ quantification. Aβ 40 and Aβ 42 Human ELISA kits (Invitrogen™ Corporation, Camarillo, CA, USA) were used to quantify the levels of Aβ 40 and Aβ 42 peptides in the brain soluble fractions. Quantitative determination was carried out according to the manufacturer's instructions. Aβ 40 and Aβ 42 levels were normalized to the total amount of protein from each individual sample (BCA method, Thermo Fisher Scientific, Wilmington, DE, USA). The number of APP/PS1 mice analyzed for each genotype (CB 1 +/+, CB 1 +/−, CB 1 −/−) and age (< 2, 3 and 6 months) was n = 5-6.
Gel electrophoresis and western blotting
Brain samples of mice aging 3 months were homogenized in RIPA lysis buffer (50 mM Tris/HCl buffer, pH 7.4 containing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF, protease, and phosphatase inhibitor cocktails, Roche Molecular Systems, USA). The homogenates were centrifuged for 15 min at 13,000 rpm. Protein concentration was determined with the BCA method (Thermo Scientific). Equal amounts of protein (20 μg) for each sample were loaded and separated by electrophoresis on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (10%) gels and transferred onto nitrocellulose membranes (Amersham, Freiburg, Germany). Non-specific bindings were blocked by incubation in 3% albumin in PBS containing 0.2% Tween for 1 h at room temperature. After washing, membranes were incubated overnight at 4°C with the antibodies against postsynaptic density protein-95 (PSD-95) (1:500, Invitrogen) and synaptophysin (1:4000, Novocastra). Protein loading was monitored using an antibody against β-actin (1:10,000, Abcam). Membranes were then incubated for 1 h in the appropriate HRP-conjugated secondary antibody (1:2000, Dako), and immunocomplexes were revealed by chemiluminescence reagent (ECL, Amersham). Densitometric quantification was carried out with TotalLab v2.01 software (Pharmacia, Sweden). Bands were normalized to β-actin. Six animals per genotype were analyzed. curve was analyzed with Kaplan-Meier test. Memory performance, PV + cells quantification and PSD-95 levels were analyzed with two-way ANOVA with APP/PS1 transgene and CB 1 mutation as between factors, followed by Tukey's post hoc when required. Aβ quantifications were analyzed with a Student t-test. In all the experiments, the significance level was set at p < 0.05.
Statistical analysis
Results
Reduced survival of APP/PS1 deficient for CB 1 receptors
As shown in Fig. 1A , crossing APP/PS1/CB 1 +/− males with WT/ CB 1 +/− females resulted in the generation of pups bearing six different genotypes. The Pearson's chi-squared test revealed that observed frequencies of each genotype were significantly different (χ 2 (2) = 26.71, p < 0.001) from the expected frequencies according to Mendelian laws (50% WT and 50% APP/PS1, and for each one of these genotypes 25% CB 1 +/+, 50% CB 1 +/− and 25% CB 1 −/−). Specifically, the number of APP/PS1 knockout for CB 1 receptor was drastically reduced at postnatal day 21, when the tail clips were collected for DNA isolation and genotyping. In contrast, the observed frequencies of each genotype were not significantly modified from the expected ones when analyzed in pups at embryonic day 13.5 (78 pups analyzed, data not shown), suggesting that CB 1 deficiency does not affect embryonic implantation or early development (before embryonic day 13.5) in APP/PS1 mice. Most importantly, none of the APP/PS1/CB 1 −/− mice survived more than two months, in spite they exhibited a healthy appearance and no external physical abnormalities. In at least three cases, during the daily handling of the animals, the researchers witnessed the sudden death of the APP/PS1/CB 1 −/− mice at their home cage following spontaneous seizures. Kaplan-Meier test applied to the survival curve calculated up to six months of age (without considering those animals sacrificed at 7 weeks or 3 months of age for brain samples collection) revealed a significant increase in the mortality of CB 1 mutant mice bearing the APP/PS1 transgene compared to WT mice (χ 2 (5) = 257.21, p < 0.001; Fig. 1B) . It is noticeable that the survival of APP/PS1/CB 1 +/− mice and WT/CB 1 −/− mice was also significantly reduced when compared to control animals at six months of age.
Characterization of APP/PS1/CB 1 −/− brain samples
Because of the serendipitous observation of the sudden death of a few APP/PS1/CB 1 −/− mice after spontaneous seizures, we hypothesized that the increased mortality of these mutant mice could be related to an imbalance in the excitatory/inhibitory neurotransmission in brain areas such as hippocampus, which is closely related to the occurrence of seizures. We observed that the genetic deletion of CB 1 receptors reduced the density of PV + inhibitory neurons in the hippocampus of APP/PS1 mice ( Fig. 2A-C) , as revealed two-way ANOVA (interaction between APP/PS1 and CB 1 genotypes, F (1, 13) = 5.014, p < 0.05; no significant effect of APP/PS1 or CB 1 genotypes) and subsequent post hoc test (p < 0.05 respect to WT/CB 1 −/−). The reduction in the density of neurons was specific for inhibitory PV + cells since no differences were observed in the total number of neurons in the hippocampus, as revealed the NeuN immunostaining quantification (data not shown). No significant modifications in PV + cells density were observed in APP/PS1/CB 1 +/− mice at 3 or 6 months, in spite of a tendency to decrease at 6 months when compared to APP/PS1/CB 1 +/+ animals (data not shown). Importantly, the decreased density of inhibitory neurons was not related with an increment of Aβ peptide production in APP/PS1/CB 1 −/−. Thus, the levels of soluble Aβ peptide were not modified in mutant mice (Fig. 2D ) and no Aβ plaques were observed in APP/PS1/CB 1 −/− mice at 7 weeks of age (data not shown).
CB 1 reduced expression accelerates the memory impairment associated to APP/PS1 transgene
In order to evaluate a potential contribution of CB 1 receptor deficiency to the progression of the AD-related cognitive impairment in APP/PS1 mice, and considering the impossibility to test CB 1 −/− mice due to their premature mortality, memory performance was assessed at 3 (pre-symptomatic phase in APP/PS1 mice) and 6 (early symptomatic phase) months of age in APP/PS1/CB 1 +/− mice and corresponding controls. As expected, at 6 months of age APP/PS1 mice exhibited an evident memory impairment (Fig. 3B) . Thus, two-way ANOVA revealed a significant effect of the APP/PS1 transgene (F (1, 37) = 35.772, p < 0.001), CB 1 deficiency (F (2, 37) = 4.571, p < 0.05) but no interaction between the two genotypes. Subsequent Tukey's post hoc test revealed memory impairment in APP/PS1/CB 1 +/+ (p < 0.001 respect to WT/CB 1 +/+), APP/PS1/CB 1 +/− (p < 0.001 respect to WT/CB 1 +/−) and WT/CB 1 −/− (p < 0.05 respect to WT/CB 1 +/+ and p < 0.01 respect to WT/CB 1 +/−). However, in spite that APP/ PS1 mice at 3 months do not exhibit memory impairment normally, a significant memory deficit was observed in APP/PS1/CB 1 +/−, indicating an acceleration of the cognitive impairment when CB 1 activity is reduced (Fig. 3A) . Specifically, two-way ANOVA revealed a significant effect of the APP/PS1 transgene (F (1, 46) = 5.672, p < 0.05), but no CB 1 genotype effect or interaction between the two factors at 3 months of age. Subsequent Tukey's post hoc test revealed a reduction in the recognition index in APP/PS1/CB 1 +/− when compared to APP/PS1/CB 1 +/+ (p < 0.05) and to WT/CB 1 +/− (p < 0.05). 
Reduction of CB 1 expression does not alter Aβ processing but modifies synaptic composition in APP/PS1 mice
We evaluated next whether the acceleration in memory impairment could be related to a modification in the Aβ processing, since Aβ peptide is known to induce cognitive disturbances in APP/PS1 mice. However, no significant difference was observed between the cortical Aβ burden (Fig. 4A-B) or soluble Aβ contents neither at 3 (data not shown) or 6 months of age in APP/PS1/CB 1 +/− mice (Fig. 4C) . These findings suggest that memory impairment in APP/PS1/CB 1 +/− could be related to enhanced negative consequences of Aβ production rather than to an increase in Aβ levels. We next evaluated the levels of postsynaptic density protein-95 (PSD-95) and the presynaptic protein synaptophysin, as molecular markers of synaptic density and integrity. As shown in Fig. 4D , APP/PS1/CB 1 +/− exhibited at 3 months of age a significant reduction in the PSD-95 contents when compared to WT/ CB 1 +/− (p < 0.05). No modifications in the levels of synaptophysin were observed (Fig. 4E) .
Discussion
A number of previous reports suggested that targeting the CB 1 receptor during the early stages could offer a strategy against AD, based on the neuroprotective effects against Aβ toxicity observed in certain experimental models after treatment with CB 1 receptor agonists [27, 9,2,15,18,4 ]. The present study aimed to further explore the specific contribution of CB 1 receptors to the progression of the cognitive impairment and the aberrant Aβ production typically occurring in AD by using APP/PS1 transgenic mice as an animal model of the disease.
We generated a new mouse strain by crossing APP/PS1 transgenic mice with CB 1 knockout mice. Intriguingly, the observed frequency of APP/PS1 mice lacking the CB 1 receptor at postnatal day 21 was significantly reduced respect the expected frequency according to Mendelian laws, in spite that CB 1 deficiency does not affect embryonic implantation or early development of transgenic animals, as revealed the genotyping of mice at embryonic day 13.5. These results indicate that a significant number of APP/PS1/CB 1 −/− mice died during late intrauterine life or shortly after birth. Most importantly, none of the APP/PS1 mice mutant for CB 1 receptor survived more than two months, revealing a major role for CB 1 receptor in the viability of these transgenic mice. The mechanisms underlying the increased mortality of APP/PS1 mice lacking CB 1 receptor remain to be fully elucidated. However, based on the serendipitous observation of the premature death of a few APP/PS1/CB 1 −/− mice after spontaneous seizures, we hypothesized that deficiency in CB 1 receptor could lead to an imbalance in the excitatory/inhibitory neurotransmission leading to enhanced excitability in response to Aβ peptide production that might ultimately cause lethal seizures. Our hypothesis is based on the facts that (i) patients and AD models exhibit increased seizure susceptibility associated to Aβ peptide overproduction [29, 17] , which is increased with the progression of the disease [1, 11] and (ii) the key role played by CB 1 receptor in the control of neuronal excitability and epileptiform seizures [21, 26] . In agreement with this hypothesis, we observed in APP/ PS1/CB 1 −/− mice at 7 weeks of age a decrease in the density of GABAergic inhibitory PV + cells in the hippocampus. GABAergic function is enhanced in this brain region in certain AD models and likely serves to counteract Aβ-induced neuronal overexcitation [29] . Thus, the deficiency in the inhibitory mechanisms suggested by the decrease in PV + cells density in APP/PS1/CB 1 −/− mice, together with the already known role of CB 1 receptors on hippocampal glutamatergic neurons on providing on-demand endocannabinoid-dependent protection against excitotoxic seizures [26] , could account for an aberrant hyperexcitability and the consequent incidence of life-threatening seizures in these APP/PS1 mice lacking CB 1 receptors. The specific loss of PV + cells in APP/PS1/CB 1 −/− mice could be related with the increased susceptibility to Aβ toxicity of GABAergic interneurons already reported both in patients and APP/PS1 mice [12, 31, 35, 36] . Neither the soluble levels of Aβ 40 or Aβ 42 , the most toxic form of this peptide, were altered in APP/PS1/CB 1 −/− mice, suggesting that CB 1 deficiency impaired the mechanisms of defense against Aβ detrimental effects rather than the production of this peptide. Considering the impossibility to characterize the progressive cognitive impairment of APP/PS1/CB 1 −/− mice due to their premature death, we evaluated memory performance of APP/PS1 mice expressing reduced levels of CB 1 receptor (APP/PS1/CB 1 +/−) at 3 and 6 months of age, corresponding respectively to the pre-symptomatic and to the early symptomatic phase in APP/PS1 mice. Noticeably, the reduced CB 1 receptor expression resulted in the acceleration of the memory impairment usually evidenced by APP/PS1 from 6 months of age, since APP/PS1/CB 1 +/− exhibited a significant reduction in the recognition index in the two-object recognition test at 3 months of age. This finding agrees with previous reports demonstrating that APP23 transgenic mice deficient for CB 1 receptor presented enhanced cognitive deficits [34] . WT/CB 1 −/− also exhibited a memory deficit at 6 months of age, in accordance with previous reports demonstrating an accelerated agerelated decline in cognitive functions in the absence of CB 1 receptors [5] . Neither the levels of soluble Aβ peptide or Aβ deposition were affected by the reduced CB 1 receptor expression in APP/PS1/CB 1 +/− mice, supporting our assumption about a major role for CB 1 receptor in the defense against Aβ detrimental effects rather than in the production of this peptide. However, Stumm et al. [34] revealed that APP23 transgenic mice knockout for CB 1 receptor exhibited reduced APP protein levels and Aβ plaque deposition and a recent report demonstrated that APP is able to alter membrane localization and inhibitory signalling activity of CB 1 receptor in the hippocampus of Tg2576 mice [22] . Thus, a direct or indirect participation of CB 1 receptor in Aβ processing cannot be completely ruled out.
Aβ peptide is known to induce synaptic dysfunction during early stages of AD by deregulating molecular organization of the postsynaptic density [20, 28] . Because of this, we evaluated the levels of PSD-95, one of the major scaffolding protein in the excitatory postsynaptic density and a potent regulator of synaptic strength [9] , and the levels of the presynaptic component synaptophysin, which are known to be reduced in APP/PS1 mice at advanced stages of the neurodegenerative process [38, 25] . Interestingly, APP/PS1/CB 1 +/− exhibited at 3 months of age, when APP/PS1 mice still present normal levels, a significant reduction in the PSD-95 contents but no modifications of the synaptophysin levels. PSD-95 protein has been previously demonstrated to play a key role in the retrograde synaptic signaling elicited by CB 1 receptor to regulate the activity-dependent inhibition of synaptic strength in the brain [10] . Thus, PSD-95 reduction could lead to an alteration of the synaptic dynamics that could ultimately account for the accelerated cognitive impairment observed in APP/PS1/CB 1 +/− animals.
In summary, the present study reveals that CB 1 receptor blockade reduces the life expectancy of APP/PS1 mice and accelerates their cognitive impairment, suggesting a relevant role of this receptor in the progression of AD.
